Genazzani, Alessandro D., et al
"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year" Over 65 percent of participants given the highest orforglipron dose attained an A1C level less than or equal to 6.5 percent
Meanwhile, among the current market leaders, Novo screens as the most attractive from a valuation and ESG risk perspective
A cyclic form of N6-threonylcarbamoyladenosine as a widely distributed tRNA hypermodification
Couples talk and performance pressure A lot of ED is fear of failing during sex
Randomized Placebo-Controlled and controlled Non-Inferiority phase III trials comparing Trafermin, a Recombinant human fibroblast growth factor 2, and enamel matrix derivative in periodontal regeneration in intrabony defects